Publication | Closed Access

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

Breast OncologyOncologyBreast CancerAdjuvant PaclitaxelCancer TreatmentMedicineRadiation OncologyApt TrialHer2-positive Breast Cancer